The Claim
Plasma p-tau217 levels above 0.177 pg/mL are associated with 78.9% sensitivity and 86.0% specificity for detecting amyloid-PET positivity (Centiloid > 20) in a research cohort of older adults with cognitive concerns.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In older adults with cognitive concerns, a blood test measuring p-tau217 above 0.177 pg/mL correctly identifies 78.9% of individuals with Alzheimer’s-related brain amyloid plaques and correctly rules out 86.0% of those without them.
See the scientific wording
Plasma p-tau217 levels above 0.177 pg/mL are associated with a 78.9% sensitivity and 86.0% specificity for detecting amyloid-PET positivity (Centiloid > 20) in a research cohort of older adults with cognitive concerns, enabling reliable identification of individuals with underlying Alzheimer’s pathology for confirmatory imaging.
When amyloid plaques build up in the brain, they trigger a chain reaction that causes tau proteins inside nerve cells to become abnormally phosphorylated. These altered tau proteins leak into the bloodstream, where their levels rise predictably above a specific threshold, signaling that amyloid plaques are present in the brain.
What the research says
1 studyThis blood test for p-tau217 at 0.177 pg/mL correctly finds 79 out of 100 people with brain plaques and correctly says 86 out of 100 people don’t have them — just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.